The U.S. Department of Health and Human Services, through the Administration for Strategic Preparedness and Response, awarded more than $1.4B for Project NextGen to support the development of a new generation of tools and technologies to protect against COVID-19. The awards announced today include $326M to Regeneron to support the development of a next-generation monoclonal antibody for COVID-19 prevention and $10M to Johnson & Johnson Innovation (JNJ) for a competition through Blue Knight, a BARDA-JLABS partnership.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN:
- Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention
- Regeneron Stock (NASDAQ:REGN): Analysts are Bullish Post FDA Approval
- Regeneron upgraded to Buy at Canaccord after high dose EYLEA approved
- Regeneron upgraded to Buy from Hold at Canaccord
- Regeneron price target raised to $830 from $820 at RBC Capital